Population pharmacokinetics of vancomycin in Japanese adult patients

Therapeutic Drug Monitoring

Volumn 20, Issue 2, 1998, Pages 139-148

  Yasuhara, Masato ^a   Iga, Tatsuji ^b   Zenda, Hiroshi ^c   Okumura, Katsuhiko ^d   Oguma, Takayoshi ^e   Yano, Yoshitaka ^e   Hori, Ryohei ^f  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c SHINSHU UNIVERSITY HOSPITAL   (Japan)

^d KOBE UNIVERSITY HOSPITAL   (Japan)

^e SHIONOGI AND CO LTD   (Japan)

^f KINKI UNIVERSITY   (Japan)

Author keywords

Creatinine clearance; MRSA; Nomogram; NONMEM; Population pharmacokinetics; Vancomycin

Indexed keywords

VANCOMYCIN;

ACCURACY; ALPHA HEMOLYTIC STREPTOCOCCUS; ANTIMICROBIAL ACTIVITY; ARTICLE; CALCULATION; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MONITORING; ENTEROCOCCUS FAECALIS; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BAYES THEOREM; CREATININE; DEMOGRAPHY; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; JAPAN; LEAST-SQUARES ANALYSIS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0031965768     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199804000-00003     Document Type: Article

References (43)

1. Sorrell TC, Packham DR, Shanker S, Foldes M, Munro R. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 1982;97:344-50.
2. Leader WG, Chandler MHH, Castiglia M. Pharmacokinetics optimization of vancomycin therapy. Clin Pharmacol 1995;28:327-42.
3. Matzke GR, Zhanel GG, Guay DRP. Clinical pharmacokinetic of vancomycin. Clin Pharmacokinet 1986;11:257-82.
4. Newfield P, Roizen MF. Hazards of rapid administration of vancomycin. Ann Intern Med 1979;91:581.
5. Traber PG, Levine DP. Vancomycin ototoxicity in a patient with normal renal function. Ann Intern Med 1981;95:458-60.
6. Levine DP, Cushing RD, Jui J, Brown WJ. Community-acquired methicilin-resistant staphylococcus aureus endocartidis in the Detroit Medical Center. Ann Intern Med 1982;97:330-8.
7. Ryback MJ, Albercht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Agents Chemother 1990;25:679-87.
8. Cimino MA, Rotstein C, Slaughter RL, Emrich LJ. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med 1987;83:1091-7.
9. Bryan KV, Rotschafer JC, Gilliland SS, Rodvold KA, Fitzgerald CM, Guay RP. A comparative assessment of vancomycinassociated nephrotoxicity in the young versus the elderly hospitalized patients. J Antimicrob Chemother 1994;33:811-21.
10. Wold JS, Turnipseed SA. Toxicology of vancomyin in laboratory animals. Rev Infect Dis 1981;3:S224-9.
11. Salama SE, Rotstein C. Prospective assessment of nephrotoxicity with concomitant aminoglycoside and vancomycin therapy. Can J Hosp Pharm 1993;46(2):53-9.
12. Rodvold KA, Pryka RD, Garrison M, Rotschafer JC. Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentration. Ther Drug Monit 1989;11(3):269-75.
13. Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimens: One-versus two-compartment Bayesian models. Ther Drug Monit 1989;11(4):450-4.
14. Tan CC, Lee HS, Lee EJC. Pharmacokinetics of intravenous vancomycin in patients with end-stage renal failure. Ther Drug Monit 1990;12(1):29-34.
15. Bryan KV, Guay DRP, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetics parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993;37(3):436-40.
16. Rodvold KA, Rotschafer JC, Gilliland SS, Guay DRP, Bryan KV. Bayesian forecasting of serum vancomycin concentrations with non-steady-state sampling strategies. Ther Drug Monit 1994;16(1): 37-41.
17. Uaanmuichai M, Day RB, Brater DC. Bayesian and least-squares methods for vancomycin dosing. Am J Med Sci 1987;294(2): 100-4.
18. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusion: gentamicin in burn patients. J Pharmacokinet Biopharm 1976;4(2):183-195.
19. Moellering RC, Krogstad DJ, Greenblatt DJ. Pharmaco-kinetics of vancomycin in patients with impaired renal function: a nomogram for dosage. Ann Intern Med 1981;94:343-6.
20. Moellering RC. Pharmacokinetics of vancomycin. J Antimicrob Chemother 1984;14:43-52.
21. Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother 1984;25:433-7.
22. Matzke GR, Kovarik KM, Rybak MJ, Boike SC. Evaluation of the vancomycin-clearance: creatinine clearance relationship for predicting vancomycin dosage. Clin Pharmacy 1985;4:311-5.
23. Brown DL, Mauro LS. Vancomycin dosing chart for use in patients with renal impairment. Am J Kid Dis 1988;11(1):15-9.
24. Rodvold KA, Blum RA, Fisher JH, et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988;32:848-52.
25. Pryka RD, Rodvold KA, Erdman SM. An update of drug dosing methods, Part IV: Vancomycin. Clin Pharmacokinet 1991;20(6): 463-76.
26. Marik PE, Lipman J, Kobilski S, Scribante J. A prospective randomized once- versus twice-daily amikacin dosing in critically ill adult and pediatric patients. J Antimicrob Chemother 1991:28: 753-64.
27. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-anaysis. Ann Intern Med 1996; 124(8):717-25.
28. Abbott Laboratories. Prescribed Information of TDx-Vancomycin.
29. NONMEM Project Group. In: Beal SL, Sheiner LB, eds. NON-MEM users' guides. University of California at San Francisco, 1992.
30. Mandema KM. Population pharmacokinetics and pharmacodynamics. In: Welling PG, Tse FLS, eds. Pharmacokinetics Mercel Dekker, 1995;411-50.
31. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
32. Lake KD,1 Peterson CD. A simplified dosing method for initial vancomycin therapy. Pharmacotherapy 1985;5:340-4.
33. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetic analysis program (MULTI) for microcomputers. J Pharmacobio-Dyn 1981;4:879-85.
34. Nakashima M, Katagiri K, Oguma T. Phase I studies of vancomycin hydrochroride for injection. Chemotherapy (Tokyo) 1992;40 (2):210-24.
35. Brown N, Ho DHW, Fong KLL, et al. Effect of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother 1983;23(4):603-9.
36. Golper TA, Noonan HM, Elzinga L. et al. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Clin Pharmacol Ther 1988;43(5):565-70.
37. Pachorek RE, Wood R. Vancomycin half-life in a patient with hepatic and renal dysfunction. Clin Farm 1991;10:297-300.
38. Macias WL, Mueller BA, Scarim SK. Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clin Pharmacol Ther 1991;50(6):688-94.
39. Zokufa HZ, Rodvold KA, Blum RA, et al. Simulations of vancomycin peak and trough concentrations using five dosing methods in 37 patients. Pharmacotherapy 1989;9(1):10-6.
40. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: The importance of age. Clin Pharmacol Ther 1984; 36(6):803-10.
41. Guay DRP, Bryan KV. Gilliland S, Rodvold KA. Rotschafer J. Comparison of vancomycin phamacokinetics in hospitalized elderly and young patients using a Bayesian forecaster. J Clin Pharmacol 1993;33:918-22.
42. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: Effect of age, gender, and body weight. Ther Drug Monit 1994;16(5):513-8.
43. Yu DK, Nordbrock E, Hucheson SJ, et al. Population pharmacokinetics of teicoplanin in patients with endocarditis. J Pharmacokinet Biopharm 1995;23(1):25-39.